Abstracts
General Information
Abstracts that have been selected for poster presentation have been divided into seven sessions:
- Session 1: Immunisation Strategies
- Session 2: Monitoring of T-Cell Responses
- Session 3: Targets
- Session 4: DC
- Session 5: Adoptive Transfer
- Session 6: TCRs
- Session 7: Mediators - Cytokines and Chemokines
| |
Session 1 | Session 2 | Session 3 | Session 4 |
|---|---|---|---|---|
| Title | Immunisation Strategies |
Monitoring of T-Cell Responses |
Targets | DC |
| Time | 14.15 - 15.00 | 15.15 - 16.00 | 14.15 - 15.00 | 15.15 - 16.00 |
| Chaired by | M. Schmitt (Ulm) | S. H. van der Burg (Leiden) | S. Stevanovic (Tübingen) | E. Kämpgen (Erlangen) |
|
P03 P10 P11 P14 P22 P37 P40 P47 P57 P58 |
P04 P07 P16 P20 P32 P33 P35 P49 P51 P52 |
P15 P24 P30 P34 P42 P48 P50 P56 |
P09 P17 P19 P21 P27 P43 P45 P54 P55 |
| |
Session 5 | Session 6 | Session 7 |
|---|---|---|---|
| Title | Adoptive Transfer |
TCRs | Mediators - Cytokines & Chemokines |
| Time | 14.15 - 15.00 | 15.30 - 16.00 | 15.30 - 16.00 |
| Chaired by | W. Herr (Mainz) | C. Rössig (Münster) | G. Pawelec (Tübingen) |
|
P18 P23 P25 P28 P29 P36 P41 P46 P53 |
P05 P06 P08 P12 P26 P31 |
P01 P02 P13 P38 P39 P44 |
List of poster presentations:
| P01 | t1Nanotech and Cancer metastasis: First measurement of integrin VLA-4 activation by SDF-1 on a living cell and at a single-molecule level
R. H. Eibl |
| P02 | Neoneurogenesis: A new hypothesis on the interaction of tumors with the neuro-endocrine system
K. Lang, D. Palm, B. Niggemann, K. S. Zänker, F. Entschladen |
| P03 | Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo
T. Warger, P. Osterloh, G. Rechtsteiner, M. Fassbender, V. Heib, B. Schmid, E. Schmitt, H. Schild, M. P. Radsak |
| P04 | The CIMT Monitoring Panel: Enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays
C. M. Britten, C. Gouttefangeas, M. J. P. Schoenmaekers-Welters, G Pawelec, S Koch, C. Ottensmeier, A. Mander, S. Walter, A. Paschen, J. Müller-Berghaus, A. Mackensen, I. Haas, I. M. Svane, S. R. Hadrup, P. T. Straten, M. Schmitt, K. Giannopoulos, R. Maier, H. Veelken, C. Bertinetti, A. Konur, S. Stevanovic, T. Wölfel and S. H. van der Burg |
| P05 | 2B4 signaling mediates chimeric receptor-induced tumor-specific T cell proliferation.
B. Altvater, S. Pscherer, S. Landmeier, J. Temme, H. Juergens, and C. Rossig |
| P06 | Phenotype, function, and safety of p53 TCR bicistronic GMP-suitable retroviral constructs
F. Rohrbach, G. Brandenburg, V. Wimmenauer, D. Hirsch, T. Stanislawsk, M. Theobald |
| P07 | P53 specific T-cell responses in patients with malignant and benign ovarian tumors
A. Lambeck, B.-N. Hoogeboom, N. Leffers, S. van der Burg, R. Offringa, I. Hamming, H. Klip, K. ten Hoor, M. Esajas, M. van Oven, J. Wouter Drijfhout, I. Platteel, C. Melief, H. Hollema, A. van der Zee, T. Daemen, H. Nijman |
| P08 | Endowing T lymphocytes with a new specificity by electroporation of RNA coding for a T cell receptor
N. Schaft, J. Dörrie, G. Schuler |
| P09 | Enhanced immunogenicity of DC targeted from blood to lymph nodes by introduction of a chimeric E/L-selectin molecule
J. Dörrie, N. Schaft, J. Hänig, G. J. Oostingh, M. P. Schön, C. Robert, E. Kämpgen, G. Schuler |
| P10 | Evaluation of a dendritic cell-based vaccine used in combination with chemotherapy in a murine Model of pancreatic carcinoma
M. Dauer, C. Bauer, F. Bauernfeind, M. Schnurr, S. Endres, A. Eigler |
| P11 | CD40 stimulated acute lymphoblastic cells express higher amounts of CCR7, but not IL-10
W. Łuczynski, E. Iłendo, O. Kovalchuk, M. Krawczuk-Rybak, I. Malinowska, A. Kołtan, T. Szczepanski, J. Wysocka, R. Jaworowski, I. Olejnik, L. Chyczewski, M. Matysiak, M. Wysocki, D. Sonta-Jakimczyk, M. Wieczorek |
| P12 | Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells against NK-sensitive and NK-resistant lymphoma and leukemia cells
T. Müller, C. Uherek, G. Maki, K. U. Chow, H.-G. Klingemann, T. Tonn, W. S. Wels |
| P13 | The onset of B16 melanoma is delayed by type I interferon mediated reduction of tumor vascularization and activation of immune cells
S. Roederstein, S. Indraccolo, S. Delorme, T. Tüting, T. Hinz, U. Kalinke |
| P14 | DNA vaccines encoding APC-targeted ErbB2 and NY-ESO-1 fusion proteins induce anti-tumor immune responses
A. Sloots, C. Mastini, F. Rohrbach, C. Curcio, R. Weth, E. Jäger, G. Forni, F. Cavallo, W. S. Wels |
| P15 | Identification of HLA-restricted T cell epitopes specific for the cutaneous T cell lymphoma associated antigen 1 (cTAGE-1)
W. Osen, J. Müller-Berghaus, H. Schönhaber, S. Soltek, Al. Bazhin, A. Paschen, D. Schadendorf, S. Eichmüller |
| P16 | Evidence for involvement of clonally expanded CD8+ T cells in anti-cancer immune responses in CLL patients following non-myeloablative conditioning and hematopoietic cell transplantation (HCT)
T. Kollgaard, S. L. Petersen, S. Reker Hadrup, T. Masmas, T. Seremet, M. Hald Andersen , H. O. Madsen , L. Vindelov, P. thor Straten |
| P17 | Inhibitor effect of osteosarcoma cell lines ondentritic cells type 1 and 2
M. Muraro, A. Palmero, F. Carraro, D. Rustichelli, I. Ferrero, E. Madon, F. Fagioli |
| P18 | Specific T-cell therapy for very high risk osteosarcoma patients
F. Carraro, A. Palmero, M. Muraro, M. Berger, I. Ferrero, E. Madon, F. Fagioli |
| P19 | Closed system production of dendritic cells via counterflow elutriation (ElutraTM)
M. Erdmann, D. Stoica, E. Strasser, M. Hendelmeier, G. Schuler, B. Schuler-Thurner |
| P20 | Vaccine-induced immunity against human papillomavirus type 16 in patients with intraepithelial neoplasia
M. Welters, G. Kenter, M. Löwik, R. Offringa, A. Vloon, S. van der Burg, C. Melief |
| P21 | Dendritic cells generated from elutriated monocytes under GMP-conditions can be electrotransfected with superior efficiency
N. Schub, B. Gahn, J. Catalcali, M. Staudinger, A. Humpe, A. Heiser, R. Repp, M. Gramatzki |
| P22 | Use of the a-hemolysin secretion system of Escherichia coli for antigen delivery of heterologous proteins with oncogenic potential
I. Gentschev, J. Fensterle, G. Dietrich, A. A Szalay, W.r Goebel, U. R Rapp |
| P23 | Lymphopenia-associated CD4+ T cell-mediated Colitis correlates with Homeostatic but not with Burst-like Proliferation
K. Schuster, R. Andreesen, A. Mackensen, C. Blank |
| P24 | cTAGE are potential multiple myeloma associated antigens
S. S. Sahota, A. Bazhin, M. Goonewardena, N. Zojer, D. Schadendorf, F. K. Stevenson, S. Eichmuller |
| P25 | Melanoma antigen specific CD8+ memory T cells in bone marrow of a Ret transgenic mouse model developing spontaneous melanoma
O. Speicher, A. Thölke, D. Schadendorf, V. Umansky |
| P26 | Inhibition of PD-1 surface expression by RNA interference as possible tool for improvement of tumour-specific T cell functions
L. Borkner, J. Kuball, B. Becker, R. Andreesen, A. Mackensen, Christian Blank |
| P27 | Efficient in vitro expression of the Human Reverse Transcriptase (hTERT) but impaired maturation in dendritic cells of lung cancer patients.
B. Gahn, A.-K. Brill, N. Schub, W. Klapper, U. Weingartz, I. Bolz, A. Heiser, D. Kabelitz, M. Kneba, M. Gramatzki |
| P28 | Superior antitumor CD8+ T cell responses in vitro using allogeneic healthy sibling compared to autologous patient lymphocytes
S. Kausche, T. Wehler, E. Schnürer, V. Lennerz, W. Brenner, S. Melchior, S. Strand, M. Gröne, R. Meyer, C. Huber, C. S. Falk, W. Herr |
| P29 | Acute myeloid leukemia-reactive CD8+ cytotoxic T cells can be rapidly expanded from CD62L(high)+ healthy donor lymphocytes
E. Distler, C. Wölfel, S. Pesth, N. Schornstheimer, T. C. Wehler, C. Huber, T. Wölfel, W. Herr |
| P30 | RHAMM/CD168 might represent potential target for immunotherapy of patients with B-cell chronic lymphocytic leukemia
K. Giannopoulos, I Hus, L. Li, A. Bojarska-Junak, J. Greiner, J. Rolinski, A. Dmoszynska, H. Döhner, M. Schmitt |
| P31 | Single chain T cell receptor transduced T cells need constant support from the constant alpha domain to trigger tumor reactivity
S. Thomas, R.-. Voss, R. Engel, J. Kuball, C. Huber, M. Theobald |
| P32 | Exploiting homeostasis-driven T cell proliferation: Preliminary results of a Pilot-Phase I clinical trial using an autologous tumor cell vaccine in NSCLC patients made lymphopenic and reconstituted with autologous PBMC
D. Rüttinger, H. Winter, N. K. van den Engel, M. Schiller, M. Schlemmer, H. Pohla, S. Grützner, B. Wagner, D. J. Schendel, B. A. Fox, K.-W. Jauch, R. A. Hatz |
| P33 | Broad T cell reactivity against a tumor-associated self antigen in melanoma patients and healthy individuals without obvious signs of autoimmunity
C. Erfurt, C. Heirman, K. Thielemans, S. Zhaojun, P. van der Bruggen, G. Schuler, E. S. Schultz |
| P34 | Identification of Cyclin A as a potential, widely-expressed tumor antigen
M. S. von Bergwelt-Baildon, E. Kondo, B. Maecker, L. M. Nadler, J. L. Schultze |
| P35 | Characterization of Cyclin D1 specific T cells using autologous CD40-activated B cells as APC
M. S. von Bergwelt-Baildon, E. Kondo, B. Maecker, L. M. Nadler, J. L. Schultze |
| P36 | Establishment of a specific immune response against Ewing family tumors with co-stimulating molecule CD137 and IL-2
C. D. Kühnöl, M. S. Staege, O. Diwan, L. Niu, S. Burdach, R. Mittler, J. Föll |
| P37 | Apoptotic tumor cell death is more immunogenic than necrotic tumor cell death
J. Gamrekelashvili, C. Krueger, M.P. Manns, R. von Wasielewski, F. Korangy, T.F. Greten |
| P38 | Neutrophil elastase is an inactivator of MMP-7 and counteracts MMP-7 induced apoptosis resistance of tumor cells
V. Alla, A. Kashyap, H. Heid, M. Theobald, P. R. Galle, D. Strand, S. Strand |
| P39 | Eomesodermin controls cytolytic activity of human CD8+ T cells and downregulation of eomesodermin in tumor infiltrating T cells is associated with poor tumor prognosis
I. Atreya, C. C. Schimanski, H. Dornhoff, C. Becker, E. Schnürer, M. R. Berger, D. Strand, W. Herr, P. R. Galle, M. F. Neurath |
| P40 | Anti tumor vaccines based on stabilized mRNA (RNActiveTM)
J. Probst, B. Scheel, R. Teufel, I. Hoerr, H.-G. Rammensee, S. Pascolo |
| P41 | Characterization of phenotypic and functional properties of regulatory T cells (Treg) in the Ret tg mouse model of spontaneous melanoma
S. Kimpfler, D. Schadendorf, V. Umansky |
| P42 | Elution of MHC class-I and -II peptides from a melanoma cell line, which stimulate T cell responses by autologous patient PBMC in vitro
E. Derhovanessian Badalians, L. Müller, S. Perez, T. Flad, N. Labarrière, F. Jotereau, C. Baxevanis, G. Pawelec |
| P43 | Comparative study of two preparations of human monocyte derived dendritic cells for clinical use
J. Müller-Berghaus, A. Sucker, A. Thoelke, W. Mier, U. Haberkorn, D. Schadendorf |
| P44 | Chimeric granzyme B fusion proteins for targeted induction of apoptosis in tumor cells
B. Dälken, H. Mahmud, U. Giesübel, W. Wels |
| P45 | EBI 3 deficient dendritic cells induce a CD8 mediated tumor cell death in a murine model of lung melanoma
K. Sauer, J. Maxeiner, P. Scholtes, R. Karwot, S. Finotto |
| P46 | Increased lung tumour in NFATc2 (-/-) mice mediated by defective CD8+ T cells and increased CD4+CD25+ lung T cells
J. H. Maxeiner, K. Sauer, R. Karwot, P. Scholtes, R. Wiewrodt, P. R. Galle, H. A. Lehr, S. Finotto |
| P47 | Vaccination with WT1 and Pr3 derived peptides in patients with AML/MDS and MUC1 derived peptides in patients with multiple myeloma - preliminary results
E. M. Wagner, J. Kuball, M. Wattad, C. Huber, W. Heit, M. Theobald |
| P48 | CTL specific for human CD19-derived peptides efficiently kill B-Cell malignancies
A. Cellary, E. Antunes Ferreira, N. Oehlrich, C. Lotz, C. Huber, M. Theobald |
| P49 | Crossreactivity of HER2-specific cytotoxic T cell clones with other members of the HER family
H. Conrad, K. Gebhard, J. Neudorfer, C. Peschel, H. Bernhard |
| P50 | T-cell responses against Bcr-Abl-expressing dendritic cells are dominated by Bcr-Abl-regulated antigens, and not by Bcr-Abl itself
F. Scheich, C. Peschel, H. Bernhard |
| P51 | Simultaneous ex vivo quantification of antigen-specific HLA class-I and class-II restricted T cell responses using in vitro transcribed RNA
S. Kreiter, T. Konrad, M. Sester, C. Huber, Ö. Türeci, U. Sahin |
| P52 | Fine analysis of spontaneous and vaccine-induced immune responses to the broadly-expressed cancer-testis antigen, NY-ESO-1
A. Knights, O. de la Rosa, N. Nuber, C. Renner, A. Knuth, A. Zippelius |
| P53 | In vitro priming of HCMV-specific T cells from seronegative donors
D. Rudolf, S. Walter, D. Maurer, G. Mester, H.-G. Rammensee, S. Stevanovic |
| P54 | Uvidem®, a DC-based melanoma therapeutic vaccine
E. Ferriès, K. Labroquère, C. Boccaccio, S. Martin, S. Massicard, F. Vernel-Pauillac, N. Bercovici, M.-T. Duffour, A. Nardin, E. Tartour, N. Haicheur, F. Audhuy, M. Salcedo, D. Landais, C. Robert, B. Escudier, G. McArthur, M. Prince, M.-A. Richard, J.-J. Grob, M.-T. Leccia, I. Templier, T. Lesimple, V. Quillien, C. Chabannon, F. Viret, M. Viguier, H. Bachelez, E. Vasseur, P. Saiag, M. Buffet, I. Gorin |
| P55 | Modifications of antigen coding RNA increases stability, translational efficacy and T-cell stimulatory capacity of dendritic cells
S. Holtkamp, S. Kreiter, A. Selmi, M. Koslowski, C. Huber, Ö. Türeci, U. Sahin |
| P56 | T cell epitopes derived from RCC antigen Apolipoprotein 1
I. Schneider, D. Rudolf, D. Maurer, D. Sigurdardottir, S. Stevanovic |
| P57 | RHAMM/CD168-R3 peptide vaccination of patients with hematological malignancies results in immunological and clinical responses
J. Greiner, A. Schmitt, K. Giannopoulos, L. Li, P. Liebisch, C. Wendl, J. Chen, M. Ringhoffer, P. Guillaume, G. Ritter, H. Döhner, M. Schmitt |
| P58 | CDR3-targeted DNA vaccines in B-cell lymphoma
M. Rinaldi, S. Iurescia, D. Fioretti, E. Signori, G. Tonon, V. M. Fazio |
Download:
Final-Program 2006 as PDF-file (595 KB)
